Amiloride

Generic Name: Amiloride

Brand Names: Midamor

Drug Type: Small Molecule

Chemical Formula: C_₆H_₈ClN_₇O

CAS Number: 2609-46-3

Unique Ingredient Identifier: 7DZO8EB0Z3

Background: A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Indication: For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Associated Conditions: Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria

Associated Therapies: -

Clinical Trials

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

Phase 3

Completed

Conditions: Hypertension Essential
Salt Excess
Genetic Hypertension

Interventions: Drug: Amiloride

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Ospedale San Raffaele

Target Recruit Count: 40

Registration Number: NCT06416735

Locations: 🇮🇹
San Raffaele Hospital, Milan, Lombardia, Italy

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Phase 1

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Amiloride
Drug: Bendroflumethiazide

First Posted Date: 2023-03-03

Last Posted Date: 2024-06-04

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT05753059

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene

Active, not recruiting

Conditions: Hypertension

Interventions: Drug: Amiloride
Drug: Triamterene

First Posted Date: 2021-11-18

Last Posted Date: 2023-07-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 146670

Registration Number: NCT05125237

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Amiloride in Nephrotic Syndrome

Phase 3

Terminated

Conditions: Sodium Retention
Edema
Nephrotic Syndrome

Interventions: Drug: Furosemide
Drug: Amiloride

First Posted Date: 2021-10-15

Last Posted Date: 2023-07-05

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 20

Registration Number: NCT05079789

Locations: 🇩🇪
University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany

AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium

Phase 4

Recruiting

Conditions: Bipolar Disorder

Interventions: Drug: Anhydrous Amiloride Hydrochloride
Drug: Placebo

First Posted Date: 2021-09-16

Last Posted Date: 2024-02-08

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 148

Registration Number: NCT05044611

Locations: 🇫🇷
Néphrologie, Hopital Bichat, Paris, France
🇫🇷
Néphrologie, Hôpital Henri-Mondor, Créteil, France
🇫🇷
Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat, Paris, France

Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension

Phase 4

Completed

Conditions: Resistant Hypertension

Interventions: Drug: Amiloride
Drug: Spironolactone

First Posted Date: 2020-04-02

Last Posted Date: 2024-08-26

Lead Sponsor: Yonsei University

Target Recruit Count: 118

Registration Number: NCT04331691

Locations: 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers

Early Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Amiloride

First Posted Date: 2019-11-29

Last Posted Date: 2023-03-08

Lead Sponsor: University of Utah

Target Recruit Count: 15

Registration Number: NCT04181008

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Phase 2

Recruiting

Conditions: Migraine With Aura

Interventions: Drug: Amiloride
Drug: Placebos

First Posted Date: 2019-08-21

Last Posted Date: 2024-07-10

Lead Sponsor: Centre Hospitalier Universitaire de Nice

Target Recruit Count: 40

Registration Number: NCT04063540

Locations: 🇫🇷
Hôpital Pierre Wertheimer, Bron, France
🇫🇷
CHU Gabriel Montpied, Clermont-Ferrand, France
🇫🇷
AP-HM, Marly, France

and more 2 locations

ENAC Blockade and Arterial Stiffness

Phase 2

Active, not recruiting

Conditions: Overweight and Obesity
Insulin Resistance

Interventions: Drug: Amiloride Pill
Drug: Placebo - Cap

First Posted Date: 2019-02-12

Last Posted Date: 2025-01-08

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 157

Registration Number: NCT03837626

Locations: 🇺🇸
University of Missouri Hospital and Clinics, Columbia, Missouri, United States

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

Phase 4

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: Amiloride
Drug: Hydrochlorothiazide

First Posted Date: 2017-05-31

Last Posted Date: 2020-09-18

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT03170336

Locations: 🇨🇳
Nephrology Dept,Guangdong General Hospital, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy